Clinical Trial Update: Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.

View source ↗

Summary

Completed real-world outcomes study in Spain evaluating COPD patients starting the triple inhaled therapy Trixeo (budesonide/glycopyrronium/formoterol).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Trixeo

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Status: COMPLETED